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Abstract
Introduction Mycosis fungoides (MF) is a non-Hodgkin’s T-cell lymphoma of the skin that often begins as limited
patches and plaques with slow progression to systemic involvement. Narrowband ultraviolet (UV) B therapy has
been proven to be an effective short-term treatment modality for clearing patch-stage MF. The effect of psoralen
plus long-wave ultraviolet A (PUVA) in the treatment of patch- and plaque-type MF has also been thoroughly
documented.
Objectives The purpose of this study was to compare the efficacy and safety of narrowband UVB and PUVA in
patients with early-stage MF.
Methods We analysed the response to treatment, relapse-free survival and irradiation dose in 114 patients with
histologically confirmed early-stage MF (stage IA, IB and IIA).
Results A total of 95 patients were treated with PUVA (83.3%) and 19 with narrowband UVB (16.7%). With PUVA,
59 patients (62.1%) had a complete response (CR), 24 (25.3%) had a partial response (PR) and 12 (12.6%) had a
failed response. Narrowband UVB led to CR in 12 (68.4%) patients, PR in 5 (26.3%) patients and a failed response
in 1 (5.3%) patient. There were no differences in terms of time to relapse between patients treated with PUVA and
those treated with narrowband UVB (11.5 vs. 14.0 months respectively; P = 0.816). No major adverse reactions were
attributed to the treatment.
Conclusions Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in
patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It
suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF.
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Introduction
Cutaneous T-cell lymphoma (CTCL) describes a heterogeneous
group of neoplasms of skin-homing T cells that show considerable
variation in clinical presentation, histological appearance, immu-
nophenotype and prognosis. Mycosis fungoides (MF) is the most
common form of CTCL and accounts for approximately 50% of
all primary cutaneous lymphomas, with an estimated incidence of
0.3 ⁄100 000 inhabitants per year.1
Early-stage MF presents as erythematous, slightly scaling patches
or plaques, in a limited or generalized distribution, with no
systemic involvement. It has been treated with various agents,
including topical potent corticosteroids, topical nitrogen mustard,
topical carmustine, electron-beam radiotherapy, interferon-a, reti-
noids and topical bexarotene.2 Based on the frequent occurrence
of lesions in non-exposed areas, ultraviolet (UV) radiation therapy
has long been used to induce remission in those patients. Broad-
band UVB and psoralen plus ultraviolet A (PUVA) have been
widely used modalities for treatment of MF, but psoralen-related
side-effects and long-term risk of photocarcinogenesis are not neg-
ligible.3 As successful use of narrowband UVB phototherapy for
MF is being reported,4–11 this treatment option has become more
widespread. In psoriatic patients, as they represent the largest
group of patients receiving phototherapy, narrowband UVB is
reported to have the same efficacy when compared with PUVA,
but with fewer side-effects,12 and reduced risk of carcinogenicity.13
The work reported in this manuscript has not received financial sup-
port from any pharmaceutical company or other commercial source.
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We therefore decided to conduct a retrospective study of our
experience to determine how the use of narrowband UVB com-
pares with that of PUVA for early-stage MF.
Materials and methods
Patient population
A retrospective search of the patient database of the Photoderma-
tology Unit in the Department of Dermatology of Hospital dos
Capuchos was carried out to identify patients with histologically
proven early-stage MF who were treated for the first time with
either PUVA or narrowband UVB. All patients had stage IA, IB or
IIA disease. The stage of the disease was determined on the basis
of the type and extent of skin involvement, according to the Euro-
pean Organization of Research and Treatment of Cancer
(EORTC).14 Stage IA refers to MF confined to the skin with
patches and plaques covering less than 10% of the skin surface
(T1N0M0 in the TNM classification). Stage IB refers to MF con-
fined to the skin with equal to or more than 10% of patches and
plaques covering the skin surface (T2N0M0). Stage IIA refers to
MF in the skin with equal to or more than 10% of patches and
plaques covering the skin surface, and clinically abnormal periph-
eral lymph nodes but negative pathology for CTCL (T1-2N1M0).
All patients were evaluated by an ophthalmologist prior to the
start of phototherapy. Selection was not made according to sever-
ity of disease. Patients with significant comorbidities or contrain-
dications to psoralen use were preferably treated with narrowband
UVB.
Database records and patient medical charts were reviewed to
obtain data on gender, age, skin phototype, pre-treatment disease
stage, pre-treatment disease duration (considered clinically),
PUVA treatment regimen (psoralen dose, cumulative UVA dose,
treatment duration and number of treatments), narrowband UVB
treatment regimen (cumulative UVB dose, treatment duration and
number of treatments), treatment response and side-effects.
Treatment
Psoralen plus long-wave ultraviolet A therapy was conducted twice
a week, at least 3 days apart. The UVA radiation was administered
2 h after the intake of 8-methoxypsoralen 0.6 mg ⁄kg. The initial
doses of UVA were chosen according to Fitzpatrick’s skin type:
1 J ⁄ cm2 for skin type II, 1.5 J ⁄ cm2 for skin type III and 2 J ⁄ cm2
for skin type IV. Successive exposures were adjusted to skin reac-
tions and skin type. In patients with skin types III and IV, if the
previous exposure had not caused a noticeable effect, the next
exposure time was increased by 30%; if the previous exposure
induced a doubtful erythema, it was increased by 10% and if it
caused a slight erythema, the same exposure time was repeated. In
patients with skin types I and II, the dose increments were 15%
and 5% for no erythema and slight erythema respectively. Maxi-
mum UVA dose per treatment was not higher than 10 J ⁄ cm2.
Therapy was continued until more than 95% clearing of the
patient’s skin lesions had occurred (clearing phase). Maintenance
phase started once the response had reached a plateau: treatment
was continued for another 8 weeks, and then reduced to weekly
sessions for another 4–8 weeks. If the patient remained more than
95% clear, treatment was then discontinued. For patients who
achieved less than 95% clearance, PUVA treatment was continued
until no further clinical improvement was noted.
Narrowband UVB therapy was conducted thrice a week on
non-consecutive days. The first exposure given was 70% of the
predetermined minimal erythema dose on the trunk. Dose escala-
tion at each visit was made according to the previous erythema
response. If there was no erythema, 20% increments were made.
For barely perceptible erythema, the previous dose was repeated.
For well-defined erythema, one session was postponed, the same
dose was repeated and increments were reduced to 10%. In the
presence of painful erythema or bulla, sessions were postponed
until recovery; thereafter a decrease of 50% in the dose was made
and the regimen was changed to minimal increments in the fol-
lowing sessions. As with PUVA, narrowband UVB was continued
until more than 95% clearing was achieved. Maintenance therapy
was then started by tapering the frequency of the sessions: twice a
week for 4–8 weeks, and then weekly for another 4–8 weeks.
Treatment was discontinued if the patient remained clear. For
patients who responded incompletely (less than 95% clearance),
therapy was maintained until no additional clinical benefit was
reported.
Association of systemic therapies (retinoids, corticosteroids or
methotrexate) was not accounted as an exclusion criterion, but
was considered when evaluating treatment response. These cases
fell into two possible situations: patients were either unresponsive
to systemic therapies and phototherapy was then started, or
patients were unresponsive to phototherapy and a systemic ther-
apy was then initiated.
Evaluation of response and toxicity
Response was evaluated according to clinical criteria. Complete
response (CR) was defined as more than 95% clearing of skin
lesions; partial response (PR) was considered when more than
50% clearing of lesions was achieved, despite continuing treat-
ment; no response was described as less than 50% clearing of skin
lesions, with persistent skin disease despite continuing treatment.
Relapse was defined as clinically significant disease requiring fur-
ther therapy. Side-effects, and local and systemic toxicity were
recorded during the therapy.
Statistical analysis
Baseline characteristics, clinical response and recurrence rates of
patients treated with PUVA vs. narrowband UVB were compared
using the chi-squared test, Fisher’s exact test or independent sam-
ples t-test, as appropriate. Kaplan–Meier lifetime table analysis was
performed to plot relapse-free rates after phototherapy modal-
ities, and the log-rank test was used to compare them between
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treatment groups. Relapse-free survival (RFS) was defined as time
from treatment completion to local and ⁄or systemic progression.
P-values <0.05 were considered to be significant. All analyses were
performed using the SPSS 12.0 for Windows (2003, SPSS Inc.,
Chicago, IL, USA).
Results
Patient characteristics
A total of 114 patients with early-stage MF were treated with either
PUVA or narrowband UVB at our department between September
1996 and January 2007. Of these patients, 95 (46 men and 49
women; mean age 59 years, range 30–80 years) were treated with
PUVA and 19 (6 men and 13 women; mean age 68 years, range
31–87 years) were treated with narrowband UVB. The disease
stage of the patients was as follows: PUVA group, IA (n = 31), IB
(n = 57) and IIA (n = 7), and narrowband UVB group, IA
(n = 6), IB (n = 12) and IIA (n = 1). The mean disease duration
before treatment was 56.4 months in the PUVA group vs.
65.8 months in the narrowband UVB group. Except for the age,
no single baseline characteristic was significantly different between
the two groups, which accounts for the homogeneity between
them. Patients’ clinical data are summarized in Table 1.
Treatment outcome
No statistically significant differences in response were found
between the two phototherapy regimens: PUVA treatment led to
CR in 59 of 95 (62.1%) and PR in 24 of 95 (25.3%) patients,
whereas narrowband UVB treatment led to CR in 13 of 19
(68.4%) and PR in five of 19 (26.3%) patients (Table 2); there
were 12 non-responders or patients with disease progression in
the PUVA group (12.6%), and one in the narrowband UVB group
(5.3%) (P = 0.650).
There were no significant differences between the two groups in
terms of treatment duration (PUVA 15.6 months vs. narrowband
UVB 12.3 months, P = 0.248), number of treatments (PUVA 31
treatments vs. narrowband UVB 37 treatments, P = 0.382) or
associated therapies (monotherapy: 39 vs. 12 patients, retinoids:
51 vs. 7 patients, corticosteroids: 3 vs. 0 patients, methotrexate: 2
vs. 0 patients; PUVA group vs. narrowband group respectively). In
the narrowband UVB group, neither treatment duration (14.9 vs.
7.7 weeks; P = 0.183), nor the cumulative UVB dose (80.9 vs.
60.6 J ⁄ cm2; P = 0.163) was significantly shortened by the associa-
tion with systemic therapies; however, in the PUVA group, the use
of systemic therapies was associated with longer treatment dura-
tions (12.2 vs. 18.1 weeks; P = 0.014) and higher cumulative UVA
doses (144.7 vs. 93.7 J ⁄ cm2; P = 0.001). The total narrowband
UVB irradiation dose ranged from 24 to 135 J ⁄ cm2 (mean:
73.4 J ⁄ cm2) and the total UVA dose ranged from 30 to 455 J ⁄ cm2
(mean: 123.8 J ⁄ cm2).
Disease recurrence was observed in 75 of 83 (90.4%) PUVA-
treated responder patients and 15 of 18 (83.3%) narrowband
UVB-treated responder patients (P = 0.307). Two of the PUVA-
treated responder patients had systemic progression of the disease:
it occurred 4 months after discontinuing therapy by detection of
clinically and pathologically abnormal peripheral lymph nodes.
There were two other patients also in the PUVA group with sys-
temic progression, but they were non-responders. The mean
relapse-free interval for responder patients treated with PUVA
(n = 83) was 11.5 ± 1.5 months (relapse-free rate at 1 year:
30.5%) and for patients treated with narrowband UVB (n = 18),
14.0 ± 4.9 months (relapse-free rate at 1 year: 43.8%). Kaplan–
Meier lifetime table analysis revealed no significant difference in
Table 1 Clinical characteristics of study patients with early-
stage mycosis fungoides
PUVA (n = 95) Narrowband UVB
(n = 19)
Gender, n (%) Male 46 (48.4) 6 (31.6)
Female 49 (51.6) 13 (68.4)
Phototype, n (%) II 27 (28.4) 7 (36.8)
III 64 (67.4) 10 (52.6)
IV 3 (3.2) 2 (10.5)
V 1 (1.1) 0
Stage, n (%) IA 31 (32.6) 6 (31.6)
IB 57 (60.0) 12 (63.2)
IIA 7 (7.4) 1 (5.3)
Mean age*, years (range) 58.8 (30.6–80.0) 68.0 (31.0–87.7)
Mean weight, kg 69.6 ± 10.9 68.8 ± 15.2
Mean disease duration,
months (range)
56.4 (3–196) 65.8 (20–168)
PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B.
*P < 0.005.
Table 2 Overall results of photo(chemo)therapy in mycosis fun-
goides
PUVA
(n = 95)
Narrowband
UVB (n = 19)
Clinical response
CR 59 (62.1) 13 (68.4)
PR 24 (25.3) 5 (26.3)
Mean treatment duration (months) 15.6 12.3
Mean number of treatments 31 37
Mean irradiation dose (J ⁄ cm2) 123.8 73.4
Associated therapies
None 39 (41.1) 12 (63.2)
Retinoids 51 (53.7) 7 (36.8)
Corticosteroids 3 (3.2) 0
Methotrexate 2 (2.1) 0
Mean relapse-free interval (months) 11.5 14.0
Values in parentheses are percentages.
PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B; CR, complete
response; PR, partial response.
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the time to relapse between the two groups (P = 0.816) (Fig. 1).
Disease stage and the association of systemic therapies did not
influence relapse-free interval after treatment (P = 0.712 and
0.361 respectively), regardless of the type of phototherapy used.
The main treatment outcomes for treatment groups according to
stage of the disease are presented in Table 3; no statistically signifi-
cant differences were found between all the parameters tested.
Safety
A total of 18 patients treated with PUVA (18.9%) reported burn-
ing sensation or generalized erythema that impeded subsequent
treatment, four of them with blisters. Treatment had to be stopped
in two of these patients (2.1%) because of adverse events: one with
blisters on the hands, the other with generalized burning without
blistering. Gastrointestinal complaints occurred in three patients
after systemic psoralen intake. Three patients reported severe pru-
ritus and one had an easily controlled polymorphic light eruption.
Acute adverse effects reported from narrowband UVB were
burning in two patients (10.5%). One of them (5.3%) had to dis-
continue treatment. No statistically significant differences in
adverse events were found between the groups (P = 0.784).
Discussion
Narrowband UVB is being integrated into the therapeutic
approaches of early-stage CTCL.15 The success that is being
reported by several authors prompted us to evaluate the effective-
ness and safety of this treatment compared with that of the well-
established PUVA therapy.
This study shows that both narrowband UVB and PUVA
achieve similar results in terms of CR rates (68% vs. 62%). There
were no significant differences in duration (12.3 vs. 15.6 months)
and number of treatments (37 vs. 31), in the relapse rate (83% vs.
90%) or in the mean time to relapse after a response (14 vs.
11.5 months). Our narrowband UVB results are in accordance
with other published reports (Table 4). These overall results are
somewhat negatively biased by the inclusion of patients in stage
IIA who, in theory, would respond poorly to phototherapy. Actu-
ally, these patients (seven in PUVA group and one in narrowband
UVB group) had lower CR rates and shorter RFS, but their relative
weight in the analysis does not change the global tendency.
In a retrospective study comparing narrowband UVB and
PUVA treatment of early-stage (stages IA and IB) MF, Diederen
et al.16 also found no differences between CR rates [81% (17 of 21
patients) vs. 71% (25 of 35 patients)], or mean relapse-free interval
(24.5 vs. 22.8 months). In another study, Ahmad et al.17 treated
12 patients with MF (stage IA–IIB) with narrowband UVB and 28
patients with PUVA. Similar conclusions were drawn: six patients
(50%) had a CR to narrowband UVB and 18 (64%) had a CR to
PUVA; the median relapse-free interval was 11.5 months in
the first group and 10 months in the second. In a prospective
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Figure 1 Kaplan–Meier analysis of relapse-free interval of
responder patients with mycosis fungoides after psoralen plus
ultraviolet A therapy (n = 83) or narrowband ultraviolet B
(n = 18). There was no significant difference in the time to
relapse between the two groups (P = 0.816; log-rank test).
Table 3 Results of photo(chemo)therapy in mycosis fungoides according to stage
PUVA (n = 95) Narrowband UVB (n = 19)
n Treatment
duration
(weeks)
Total
dose
(J ⁄ cm2)
Clinical
response
Relapse-free
interval
(months)
n Treatment
duration
(weeks)
Total
dose
(J ⁄ cm2)
Clinical
response
Relapse-free
interval
(months)
IA 31 16.9 127.6 CR 20 (64.5)
PR 8 (25.8)
10.6 6 11.5 84.8 CR 5 (83.3)
PR 1 (16.7)
18.9
IB 57 14.1 119.6 CR 37 (64.9)
PR 15 (26.3)
12.1 12 12.6 69.2 CR 8 (66.7)
PR 3 (25.0)
13.2
IIA 7 22.7 141.1 CR 2 (28.6)
PR 1 (14.4)
7.6 1 12.4 55.1 CR 0
PR 1 (100)
1.0
Values in parentheses are percentages.
PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B; CR, complete response; PR, partial response.
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right–left comparative study, El-Mofty et al.18 tried to determine
whether the addition of psoralen into a narrowband UVB regimen
was superior to narrowband UVB alone in treating early-stage
MF, when compared with PUVA. They chose 20 patients and
divided them into two equal groups: group I received narrowband
UVB on the right body half vs. PUVA on the left side of the body,
and group II received psoralen with narrowband UVB on the right
side of the body vs. PUVA on the left side. They confirmed that
both narrowband UVB regimens were as effective as PUVA, but
that the association of psoralen with UVB did not enhance its
therapeutic efficacy.
One of the variables these three previous comparative studies
did not clearly address was the concomitant use of systemic thera-
pies. In our study, seven of the 19 patients (37%) of the narrow-
band UVB group had combination regimens, against 56 of 95
patients (59%) of the PUVA group. One of the aims of combina-
tion therapy is to lower the cumulative dose and number of treat-
ments, enhancing efficacy with higher remission rates and relapse-
free intervals.15,19 However, treatment duration and cumulative
doses were not significantly affected in the narrowband UVB
group. Paradoxically, we registered longer treatment durations
and cumulative radiation doses in the PUVA group. This finding
is probably a consequence of systemics being preferentially used
whenever a patient had a more severe or less responsive MF. How-
ever, no differences in relapse-free intervals between patients on
phototherapy associated with a systemic agent and phototherapy
alone were found in our study, which is in line with previous
reports.15,19
The mechanisms by which PUVA induces tumour regression
may involve neoplastic T-cell death, psoralen adduct damage to
cell organelles and alteration of the immune system.20,21 These
effects are elicited by nuclear damage to DNA resulting from the
interaction of psoralen with DNA, as well as generation of singlet
oxygen with subsequent cell membrane damage.22 Recent studies
on extracorporeal photopheresis attributed the induction of apop-
tosis to the dysregulation in the expression of the apoptotic genes
Bcl-2 and Bax, and an increase of Fas ⁄FasL system.23
The detailed mechanisms of action of narrowband UVB are not
well defined. The therapeutic action in MF may involve a combi-
nation of effects, including changes in cell cycle kinetics, alterations
in cytokine expression and immunomodulation. In vitro experi-
ments show that UVB interferes with Langerhans cells and antigen
presentation by reducing their viability and antigen function, and
increases interleukin 2 and interleukin 6 production by human
keratinocytes.21,24 Increased levels of tumour necrosis factor have
also been detected after UVB irradiation. Induction of T-cell apop-
tosis may also contribute to the suppression of the function of the
neoplastic population of clonal T cells in the skin.25 These effects
are achieved with a low-rate adverse effects profile.
The acute adverse events of narrowband UVB include erythema,
blistering, xerosis, pruritus and reactivation of herpes simplex.15
However, these are easily managed and do not usually preclude
treatment maintenance. Moreover, although UVB is a known car-
cinogen, its carcinogenic potential seems to be lower than that of
PUVA;26 nevertheless a small but significant increase of basal cell
carcinomas was detected in a Scottish population survey.27 In fact,
narrowband UVB produced minimal side-effects in our patients.
The adverse events rate, however, was not significantly different
from that of PUVA therapy, an observation that is probably influ-
enced by the sample size. The follow-up period was too short to
report chronic adverse effects such as photoaging and photocarci-
nogenesis.
As for PUVA, the known side-effects associated with psoralen
(nausea, vomiting and headache), the risk of excess phototoxicity,
the interaction between UVA and the ocular lens, and the docu-
mented photocarcinogenesis and photoimmunosupression are
unbalancing the choices in phototherapy towards narrowband
UVB.28 This is probably the main reason why a difference in age
was found between our two study groups (Table 1): elderly
patients frequently have more associated medical conditions that
might contraindicate the use of PUVA.
This study confirms that phototherapy is a safe, effective and
well-tolerated therapy in patients with early-stage CTCL, signifi-
cantly delaying the time to recurrences. It should be expected of
UVA to reach a better response initially and a longer disease-free
remission because of the deeper radiation penetration. However,
our results indicate that narrowband UVB is at least as effective as
PUVA in treatment of early-stage MF. Larger series of patients are
still needed, but as the use and indications of narrowband UVB
phototherapy continue to increase, this study strengthens its role
as a first-line therapy in MF.
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